Recruiting

Testing a new medication combined with CAR-T cell therapy for advanced blood cancer

Plain-English translation of NCT06458439 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether — a new type of medication — can help people with advanced lymphoma when used alongside CAR-T cell therapy. CAR-T cell therapy is a powerful treatment where your own immune cells are trained in a lab to fight your cancer and then put back into your body. This study is checking whether the medication works both before the CAR-T cells are infused and afterward, especially if any cancer remains.

Many people with advanced lymphoma no longer respond to standard chemotherapy and antibody treatments. CAR-T cell therapy has helped some patients, but others still have cancer left afterward or the cancer comes back. This trial is exploring whether this new medication could improve outcomes by working alongside CAR-T cells at different stages of treatment.

Do you qualify?

You likely qualify if…

you are over 18 years old
you have been diagnosed with a large B-cell lymphoma that has either stopped responding to or returned after initial chemotherapy and antibody treatment
your cancer cells have been confirmed by biopsy to have a specific marker called CD20
you are eligible and willing to receive an FDA-approved CAR-T cell therapy
you have measurable disease visible on imaging scans (like CT or PET scans)
your overall health and blood work are adequate enough for this treatment, as determined by the study team

You likely don't qualify if…

you have had a previous organ transplant
you have lymphoma that has spread to your brain or spinal fluid
you have an active autoimmune disease or require long-term immunosuppressive medications (with some specific exceptions for conditions like thyroid disease or mild skin conditions)
you are unable or unwilling to provide informed consent or follow the study protocol
you have not recovered from side effects of prior cancer treatments

What participation looks like

You would receive weekly infusions of the medication for three cycles (about 3 weeks per cycle), with doses given on days 1, 8, 15, and 22 of each cycle. After this initial phase, you would proceed to receive your CAR-T cell therapy as planned. If cancer remains after the CAR-T cells, you may receive more doses of the medication. Throughout the study, you'll have blood tests, imaging scans, and regular visits with the research team to monitor how you're responding and check for side effects.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Trial locations(1 site)

United States

Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania